Pharmaceutical Information |
Drug Name |
Cytarabine hydrochloride |
Drug ID |
BADD_D00561 |
Description |
A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472) |
Indications and Usage |
For the treatment of acute non-lymphocytic leukemia, acute lymphocytic leukemia and blast phase of chronic myelocytic leukemia.
Cytarabine is indicated in combination with [daunorubicin] for the treatment of newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC) in adults and pediatric patients 1 year and older.[L32843] |
Marketing Status |
approved; investigational |
ATC Code |
L01BC01 |
DrugBank ID |
DB00987
|
KEGG ID |
D03637
|
MeSH ID |
D003561
|
PubChem ID |
6252
|
TTD Drug ID |
D07XSN
|
NDC Product Code |
71288-168; 61703-304; 55512-0026; 25021-229; 61703-319; 68083-343; 71288-108; 12848-1003; 71288-109; 71288-169; 58623-0026; 61703-303; 63323-120; 68083-337; 61703-305; 67430-075; 25021-223 |
UNII |
33K3DB6591
|
Synonyms |
Cytarabine | Arabinosylcytosine | Cytosine Arabinoside | Arabinoside, Cytosine | Arabinofuranosylcytosine | Aracytidine | beta-Ara C | beta Ara C | Cytarabine Hydrochloride | Cytosar | Cytosar-U | Cytosar U | Ara-C | Ara C | Aracytine | Cytonal |
|
Chemical Information |
Molecular Formula |
C9H13N3O5.ClH |
CAS Registry Number |
69-74-9 |
SMILES |
C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)O.Cl |
Chemical Structure |
|
|
ADRs Induced by Drug |
|
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
|
|